First do no harm—beware the risk of therapeutic plasma exchange in severe COVID-19
Open Access
- 18 June 2020
- journal article
- letter
- Published by Springer Nature in Critical Care
- Vol. 24 (1) , 1-2
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- First do no harm—beware the risk of therapeutic plasma exchange in severe COVID-19Critical Care, 2020
- Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19New England Journal of Medicine, 2020
- Endothelial cell infection and endotheliitis in COVID-19The Lancet, 2020
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJAMA, 2020
- A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19Critical Care, 2020
- Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shockCritical Care, 2020
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special IssueJournal of Clinical Apheresis, 2019
- Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markersCritical Care, 2018
- Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A—An associated respiratory failure and hemodynamic shockPediatric Critical Care Medicine, 2011
- Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trialIntensive Care Medicine, 2002